{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T06:38:02Z","timestamp":1781419082744,"version":"3.54.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"publisher","award":["DE230101042"],"award-info":[{"award-number":["DE230101042"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The Natural Killer T cells (NKT) are a unique subset of T lymphocytes that recognize lipid-based antigens that are presented by the monomorphic MHC-I-like molecule, CD1d. Over 30 years ago, the discovery of the glycolipid \u03b1-Galactosylceramide (\u03b1-GalCer) from the marine sponge <jats:italic>Agelas mauritianus<\/jats:italic>, as a potent activator of the invariant Natural Killer T (iNKT) cells, has attracted great attention for its use in cancer immunotherapy. However, \u03b1-GalCer can initiate both pro-inflammatory T helper cell 1 (Th1) and anti-inflammatory Th2 type immune responses that can result in either enhanced or suppressed immunity in a somewhat unpredictable manner. Th1 polarized immune response is often correlated with an optimal anti-tumor immunity, and therefore \u03b1-GalCer did not fully offer the desired potential as an anti-tumor therapeutic. Over the past decades, considerable efforts have then been invested into the design and development of novel synthetic \u03b1-GalCer analogues that will direct a more efficient immune response towards the production of Th1 biased cytokines. In this minireview, we will discuss how subtle modifications in the chemical nature of a number of \u03b1-GalCer derivatives varied immune responses. Whilst some of these analogues showed potential in enhancing stability within CD1d and directing favourable immune responses for tumor immunotherapy, their responses in mice also highlighted the need for further research in humanized models to overcome translational challenges and optimize therapeutic efficacy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1479382","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T09:19:34Z","timestamp":1732785574000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["State of play in the molecular presentation and recognition of anti-tumor lipid-based analogues"],"prefix":"10.3389","volume":"15","author":[{"given":"T.","family":"Praveena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Le Nours","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.02.004","article-title":"The fidelity, occasional promiscuity, and versatility of T cell receptor recognition","volume":"28","author":"Godfrey","year":"2008","journal-title":"Immunity"},{"key":"B2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-032414-112334","article-title":"T cell antigen receptor recognition of antigen-presenting molecules","volume":"33","author":"Rossjohn","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nri1309","article-title":"NKT cells: what\u2019s in a name","volume":"4","author":"Godfrey","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200423594","article-title":"Going both ways: immune regulation via CD1d-dependent NKT cells","volume":"114","author":"Godfrey","year":"2004","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2009.10.004","article-title":"Antigen recognition by CD1d-restricted NKT T cell receptors","volume":"22","author":"Godfrey","year":"2010","journal-title":"Semin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.03.009","article-title":"Unconventional T cell targets for cancer immunotherapy","volume":"48","author":"Godfrey","year":"2018","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/jm00012a018","article-title":"Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice","volume":"38","author":"Morita","year":"1995","journal-title":"J Med Chem"},{"key":"B8","article-title":"KRN7000, a novel immunomodulator, and its antitumor activities","volume":"7","author":"Kobayashi","year":"1995","journal-title":"Oncol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5343.1626","article-title":"CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides","volume":"278","author":"Kawano","year":"1997","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.8.1529","article-title":"CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells","volume":"188","author":"Spada","year":"1998","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-04-1155","article-title":"Therapeutic activation of V\u03b124+V\u03b211+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity","volume":"103","author":"Nieda","year":"2004","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1453","article-title":"A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer","volume":"11","author":"Ishikawa","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20042592","article-title":"Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients","volume":"201","author":"Chang","year":"2005","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01135.x","article-title":"Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma","volume":"100","author":"Kunii","year":"2009","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2010.11.014","article-title":"Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy","volume":"138","author":"Yamasaki","year":"2011","journal-title":"Clin Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/35097097","article-title":"A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing T(H)2 bias of natural killer T cells","volume":"413","author":"Miyamoto","year":"2001","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407488102","article-title":"Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides","volume":"102","author":"Yu","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031192","article-title":"Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide","volume":"198","author":"Schmieg","year":"2003","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2713","article-title":"CD1d-lipid antigen recognition by the gammadelta TCR","volume":"14","author":"Uldrich","year":"2013","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141764","article-title":"The molecular bases of delta\/alphabeta T cell-mediated antigen recognition","volume":"211","author":"Pellicci","year":"2014","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"10570","DOI":"10.1038\/ncomms10570","article-title":"Atypical natural killer T-cell receptor recognition of CD1d-lipid antigens","volume":"7","author":"Le Nours","year":"2016","journal-title":"Nat Comm"},{"key":"B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nri2451","article-title":"Harnessing invariant NKT cells in vaccination strategies","volume":"9","author":"Cerundolo","year":"2009","journal-title":"Nat Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2249.2012.04625.x","article-title":"Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality","volume":"171","author":"Simoni","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ni1225","article-title":"The crystal structure of human CD1d with and without alpha-galactosylceramide","volume":"6","author":"Koch","year":"2005","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ni1224","article-title":"Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor","volume":"6","author":"Zajonc","year":"2005","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.immuni.2009.04.018","article-title":"Differential recognition of CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T cell receptors","volume":"31","author":"Pellicci","year":"2009","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature05907","article-title":"CD1d-lipid-antigen recognition by the semi-invariant NKT T-cell receptor","volume":"448","author":"Borg","year":"2007","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1021\/ar050006z","article-title":"Alpha-c-galactosylceramides: synthesis and immunology","volume":"39","author":"Franck","year":"2006","journal-title":"Acc Chem Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604812103","article-title":"Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice","volume":"103","author":"Fujii","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2011.145","article-title":"Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis","volume":"30","author":"Aspeslagh","year":"2011","journal-title":"EMBO J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100794","article-title":"NKT TCR recognition of CD1d-alpha-C-galactosylceramide","volume":"187","author":"Patel","year":"2011","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.654814","article-title":"Lipid and carbohydrate modifications of alpha-galactosylceramide differently influence mouse and human type I natural killer T cell activation","volume":"290","author":"Birkholz","year":"2015","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200900193","article-title":"Aminocyclitol-substituted phytoceramides and their effects on iNKT cell stimulation","volume":"4","author":"Harrak","year":"2009","journal-title":"ChemMedChem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1103049","article-title":"Structural and functional characterization of a novel nonglycosidic type I NKT agonist with immunomodulatory properties","volume":"188","author":"Kerzerho","year":"2012","journal-title":"J Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jmb.2009.08.061","article-title":"Structural evaluation of potent NKT cell agonists: implications for design of novel stimulatory ligands","volume":"394","author":"Schiefner","year":"2009","journal-title":"J Mol Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1021\/ja062740z","article-title":"Structure-based discovery of glycolipids for CD1d-mediated NKT cell activation: tuning the adjuvant versus immunosuppression activity","volume":"128","author":"Fujio","year":"2006","journal-title":"J Am Chem Soc"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1021\/ja8012787","article-title":"Quantitative microarray analysis of intact glycolipid-CD1d interaction and correlation with cell-based cytokine production","volume":"130","author":"Liang","year":"2008","journal-title":"J Am Chem Soc"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006662107","article-title":"Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant","volume":"107","author":"Li","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500070","article-title":"A novel glycolipid antigen for NKT cells that preferentially induces IFN-gamma production","volume":"195","author":"Birkholz","year":"2015","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2011.10.015","article-title":"Glycolipids that elicit IFN-gamma-biased responses from natural killer T cells","volume":"18","author":"Tyznik","year":"2011","journal-title":"Chem Biol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902880","article-title":"Mechanisms for glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells","volume":"184","author":"Sullivan","year":"2010","journal-title":"J Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.02.001","article-title":"A molecular basis for the exquisite CD1d-restricted antigen specificity and functional responses of natural killer T cells","volume":"34","author":"Wun","year":"2011","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.03.022","article-title":"Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation","volume":"30","author":"Im","year":"2009","journal-title":"Immunity"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1038\/s41598-017-04461-7","article-title":"Galactosylsphingamides: new alpha-GalCer analogues to probe the F\u2019-pocket of CD1d","volume":"7","author":"Guillaume","year":"2017","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2015.04.068","article-title":"Synthesis of C-5\u2019\u2019 and C-6\u2019\u2019-modified alpha-GalCer analogues as iNKT-cell agonists","volume":"23","author":"Guillaume","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1039\/c1ob06235b","article-title":"Divergent synthetic approach to 6\u2019\u2019-modified alpha-GalCer analogues","volume":"9","author":"Pauwels","year":"2011","journal-title":"Org Biomol Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1203134","article-title":"Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection","volume":"191","author":"Aspeslagh","year":"2013","journal-title":"J Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1039\/D1CB00251A","article-title":"6\u2019\u2019-Modifed alpha-GalCer-peptide conjugate vaccine candidates protect against liver-stage malaria","volume":"3","author":"Meijlink","year":"2022","journal-title":"RSC Chem Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.chembiol.2018.06.008","article-title":"Dual modifications of alpha-galactosylceramide synergize to promote activation of human invariant natural killer T cells and stimulate anti-tumor immunity","volume":"25","author":"Chennamadhavuni","year":"2018","journal-title":"Cell Chem Biol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04083-0","article-title":"Host immunomodulatory lipids created by symbionts from dietary amino acids","volume":"600","author":"Oh","year":"2021","journal-title":"Nature"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1574591","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1479382\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T10:12:06Z","timestamp":1740651126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1479382\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2024.1479382"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1479382","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2025.1574591","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"article-number":"1479382"}}